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research area. Gel as dosage forms were successfully used 
as drug delivery systems with their ability to prolong 
the drug release. Topical, self-administered products 
containing HIV microbicides were aimed to prevent and 
to reduce HIV infection in women and may represent the 
most promising strategy for combating the HIV/AIDS 
epidemic at the present time. The vagina is an efficient 
route[2] for drug administration due to presence of dense 
blood vessels network and avoids first-pass.[3,4] Ideally, anti-
HIV vaginal gels (F) should adheres in vaginal medium; 
provide uniform drug–hydrogel coating of vaginal tissue, 
resulting in intravaginal biomimetic lubrication during 
intercourse, and retention of this gel layer before and after 
intercourse. Most importantly, controlled release of anti-
HIV drugs form this gel inactivates the viral load potentially 
INTRODUCTION
The women (15.4 million) are approximately 50% of people 
(33.2 million) infected and living with HIV, as reported in 
2007 UN AIDS summary.[1] In most regions of the world, 
HIV is affecting women and girls in increasing numbers. 
Vaginal drug delivery is a very challenging and less explored 
Pharmaceutics
Formulation, In Vitro and In Vivo Pharmacokinetics of Anti-HIV 
Vaginal Bioadhesive Gel
Chatterjee A, Bhowmik BB, Thakur YS 
Department of Pharmaceutics, Himalayan Pharmacy Institute, Majhitar, Rangpo, East Sikkim, India 
Address for correspondence: Mr. Arkendu Chatterjee; E-mail: arkendu2001@yahoo.co.in
ABSTRACT
Inexpensive and female-controlled pre-exposure prophylaxis strategies to prevent mucosal transmission of the 
virus, is urgently needed with the rising prevalence of human immunodeficiency virus (HIV-1 and HIV2) infections 
in women. Zidovudine-loaded bioadhesive vaginal gel may become one of the very useful strategies, as it can be 
used not only for controlled release but also for enhancing bioavailability. Drug delivery through vaginal gel is a 
promising area for continued research with the aim of achieving controlled release with enhanced bioavailability 
over longer periods of time. The aim of the study was to develop a newer prolong releasing Zidovudine (AZT) 
bioadhesive vaginal gel to treat HIV infections with increased patient convenience. AZT-loaded bioadhesive 
vaginal gel was prepared successfully by using cold mechanical method. F3 formulation containing carbopol–
HPMC (1:3) was selected and evaluated in order to achieve objectives of this study. In vitro drug release study 
of F3 showed in 24 h drug released following case I Fickian (n ≤ 0.5) transport mechanism, and in vivo drug 
release was found much better (Tmax), (Cmax), and bioavailability (F) comparison with oral pour drug solution. 
It was also showed good extrudability, spreadability, and bioadhesive strength. A generalized protocol, for the 
further research, in this area will surely expected to yield significant outcome with improved drug delivery system.
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introduced during sexual activity. Zidovudine (AZT) with 
short elimination half-life of about 1 h, high dose (250 mg 
in every 4 h while 300 mg twice a day, in some cases), low 
systemic bioavailability (64%) due to rapid hepatic fast-pass 
metabolism, was chosen as a model drug of choice.[5] The 
use of prolong-release bioadhesive vaginal gel was thought 
to offer numerous benefits including prolong residence 
time of the dosage form at the site of absorption due to 
bioadhesion to the vaginal mucosa, prolong drug release, 
improved bioavailability and decreased side effect of drug, 
and ultimately improved patient compliance. Keeping in 
view of the above uniqueness, this study was designed to 
develop a newer formulation for prolong release of AZT 
to treat HIV infections with increased patient convenience.
MATERIALS AND METHODS
Materials
Zidovudine was obtained from Arbindo Pharmaceutical 
Ltd. (Hydrabad, India). Carbopol 940P were received 
as gift sample from Corel Pharma Chem (Ahmedabad, 
India). HPMCK4M was obtained from LOBA Chemicals 
(Kolkata, India). All other chemicals and reagents used 
were of analytical grade and used as received.
Methods
Preparation of  Zidovudine-loaded vaginal gel
Vaginal gels were prepared by cold mechanical method 
described by Schmolka.[6,7] The required quantity of drug 
(AZT) and polymer (Carbopol 940P and HPMCK4M) 
was weighed, then it was sprinkled slowly on surface 
of purified water for 2 h. After that it was continuously 
stirred by mechanical stirrer, till the polymer was soaked 
in the water. Finally solution was kept for overnight for 
complete hydration of polymer. With continuous stirring, 
triethanolamine was added to neutralize the gel and to 
maintain the pH of the gel. Now the appropriate quantity 
of dimethyl sulphoxide (DMSO) was added to the gel, 
which behaved as the penetration enhancer, followed by 
addition of required quantity of ethanol to make the soft 
gel. Care should be taken to avoid incorporation of air into 
gel. In this way, four formulations (F1–F4) of gel were 
prepared by combinations of carbopol 940 and HPMC. 
Finally, the preparations were packed in wide mouth plastic 
jar covered with screw capped plastic lid after covering the 
mouth with an aluminum foil and were kept in dark and 
cool place. The formulations were preserved for further 
study. The generalized bioadhesive gel preparation protocol 
depends on choice of solvent, stirring speed of mechanical 
stirrer, and optimization at every preparative steps. AZT 
incorporated into bioadhesive gel intended for vaginal was 
successfully prepared using mechanical stirring technique 
as designed in Table 1.
Percent yield of  vaginal gel
The percent yield was calculated[8] as the weight of the 
formulations (Fs) recovered from each batch divided by 
total weight of drug containing microparticles and other 
all ingredients used to prepare Fs multiplied by 100. The 
percentage yield of each formulation was replicated three 
times. The yield of Fs was calculated using the following 
formula:
Y = {Pm - Zg}/Tm[P + Ig] × 100,
 
where Y = yield, Pm = practical mass, ZG = vaginal gel, 
Tm =theoretical mass, P = polymer, and Ig = ingredients.
Drug content evaluation
Drug content was determined by Sanjay et al.,[9] dissolved 
accurately weighed quantity of bioadhesive vaginal gel with 
20 mL of simulated vaginal fluid (SVF, acetate buffer I.P. 
pH 4.7) in a 50 mL of volumetric flask with continuous 
stirring. The volume was adjusted up to 50 mL with SVF. 
Blank bases were also treated in similar manner for blank 
determination. Both the test sample and blank were allowed 
to stand on mechanical stirrer for 2 h and kept for 24 h. In 
the next day, all the solutions were filtered using Whatmann 
filter paper no. 44. Then, the filtrate solution was kept as a 
stock solution. After suitable dilution, the absorbance of 
the solution with the blank was measured by UV–visible 
spectrophotometer (UV-1700, Shimadzu, Japan) at 267 nm. 
Drug content was calculated from the standard calibration 
curve, Y = 0.038 × X, where Y = absorbance and X = 
concentration of the drug. Dc = [Cc ×Df × V]/CF, where 
as Dc = drug content, CC = concentration, DF = dilution 
factor, V = volume taken, and CF = conversion factor.
Bioadhesive strength of  Fs using isolated goat vagina
Isolated goat vaginal tissue (Capra hircus, local breed, 
Table 1: Formulation design of bioadhesive vaginal gels 
(F1–F4) 
Ingredients Formulation
F1 F2 F3 F4
Zidouvdine (mg) 100 100 100 100
Carbopol (mg) 100 100 100 100
HPMC (mg) 100 200 300 400
DMSO (mL) 0.2 0.2 0.2 0.2
Triethanolamine (mL) 0.9 0.9 0.9 0.9
Methyl  Paraben (mg) 15 15 15 15
Alcohol (mL) 5.0 5.0 5.0 5.0
Water (up to mL) 100 100 100 100
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obtained immediately after killing of animals at a slaughter 
house) was cleaned and then separated from the supporting 
muscular and connective tissues taking care to maintain 
integrity of mucosa, and kept at 0°C till further use. Before 
experiments, goat vaginal tissue was thawed in normal 
saline. The bioadhesion measurement was performed using 
a modified balance method intact with freshly excised goat 
vaginal mucosal membrane as an in vitro model.[10] The two 
pans of physical balance were removed. Right side pan was 
replaced with a 100 mL beaker and on left side, a glass slide 
was hanged. For balancing the assembly, a weight of 20 
g was hanged on left side. Another glass slide was placed 
below the hanged slide. Portions of vaginal membranes 
were attached with both slides. The height of this setup was 
so adjusted, in such a way that it leaves a space of about 
0.2 cm between two vaginal membrane faces. One gram of 
gel was placed between two vaginal membrane faces. Little 
pressure was applied to form bioadhesion bond, and then 
slowly drop of water was added on right side beaker, till 
the gel was separated from one face of vaginal membranes 
attached. Volume of water added was converted to mass. 
This gave the bioadhesive strength of gel in gm. An initial 
investigation examined the reproducibility of the system 
using five same formulations. Then, the study was carried 
out for all formulations.[11]
Spreadability of  vaginal gels
Spreadability was determined[12] by apparatus suggested 
by Mutimer which was suitably modified in the laboratory 
and used for the study. It consists of a wooden block, 
which was provided by a pulley at one end. By this method, 
spreadability was measured on the basis of “Slip” and 
“Drag” characteristics of gels. A ground glass slide was 
fixed on this block. An excess of gel about 2 g under 
study was placed on this ground slide. The gel was then 
sandwiched between this slide and another glass slide 
having the dimension of fixed ground slide and provided 
with the hook. One kilogram weight was placed on the top 
of the two slides for 5 min to expel the air and to provide 
a uniform film of the gel between the slides. Excess of the 
gel was scrapped off from the edges. The top plate was then 
subjected to pull of 80 g. With the help of string attached 
to the hook and the time (in seconds) required by the top 
slide to cover a distance of 7.5 cm be noted. A shorter 
interval indicates better spreadability.[13] Spreadability was 
then calculated using the following formula:
S = Mg × Ls/Tm, 
where S is the spreadability, Mg is the weight in the pan 
(tied to the upper slide), Ls is the length moved by the glass 
slide, and Tm represents the time taken to separate the slide 
completely from each other.
Extrudability of  vaginal gels
It is a usual empirical test to measure the force required 
to extrude the material from tube. The method applied 
for determination[13] of applied shear in the region of the 
rheogram corresponding to a shear rate exceeding the 
yield value and exhibiting consequent plug flow one such 
apparatus is described by Chakole. In this study, the method 
adopted for evaluating gel formulation for extrudability 
was based upon the quantity in percentage of gel and 
gel extruded from lacquered aluminum collapsible tube 
on application of weight in grams required to extrude at 
least 0.5 cm ribbon of gel in 10 s. The measurement of 
extrudability of each formulation was in triplicate and the 
average values are presented. The extrudability was than 
calculated using the following formula:
EP = Gm/A, 
where EP is extrudability, Gm is applied weight to extrude 
gel from tube (in g) and A is area (in cm2).
In vitro drug diffusion studies of  vaginal gel
In vitro drug diffusion studies were carried out using 
biochambered donor receiver compartment model, 
Keshery–Chien diffusion cell. Cellophane membrane was 
stored in SVF. The cellophane membrane acts like a barrier 
between the gel and the SVF (sink phase). One gram of 
gel was placed on the surface of processed cellophane 
membrane, and membrane was fixed to one end of the 
cylindrical donor compartment by adhesive tape such that 
the lower end of tube containing film just touched the 
surface of SVF medium. In addition, 0.5 mL of SVF was 
placed and maintained at same level throughout the study in 
the donor compartment. Temperature was maintained at 37 
± 2°C with constant stirring at 50 ± 10 rpm. A quantity of 5 
mL sample was withdrawn from the receptor compartment 
at definite time interval and replaced with 5 mL of SVF 
to maintain constant volume. The drug was estimated by 
using Schimadzu UV–Visible spectrophotometer at 267 
nm (λmax).[14] 
Drug release kinetic studies of  gel formulations
To study the exact mechanism of drug release from the 
vaginal bioadhesive gel, drug release data were analyzed 
according to zero-order, first-order, Higuchi square 
root, and Korsmeyer–Peppa’s equations. The criterion 
for selecting the most appropriate model was chosen on 
the basis of goodness of fit test.[15,16] To investigate the 
mechanism of AZT release from gel formulations, the 
release data were analyzed with the following mathematical 
models: Zero-order kinetic (equation a), first-order kinetic 
(equation b), and Higuchi kinetic (equation c).
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 Qt  = K0t  ---------- (a)
ln Qt = ln Q0 – K1t  ---------- (b)
 Qt = Kht1/2  ---------- (c)
The following plots were made: Qt versus t (zero-order 
kinetic model), ln (Q0 – Qt) versus t (first-order kinetic 
model), and Qt versus t1/2. Here, Qt is the percent of drug 
released at time t, Q0 is the percent of drug present in 
the microparticles, K0, K1, and Kh are the constants of the 
equations.
Further, to confirm the mechanism of drug release, the 
first 60% of drug release was fitted in Korsmeyer–Peppas 
model (equation d):
Mt/Mα = KPtn,   ---------- (d)
where (Mt/Mα) is the fraction of the drug release at time (t), 
KP is the rate constant, n the value is used to characterize 
different release mechanisms, and is calculated from the 
slope of log of fraction of drug released (Mt/Mα) versus 
of time (t).
The following plots were made: cumulative % drug release 
versus time (zero-order kinetic models); log cumulative of 
% drug remaining versus time (first-order kinetic model); 
cumulative % drug release versus square root of time 
(Higuchi model); and log cumulative % of drug released 
versus log time (Korsmeyer–Peppas model).
In vivo study of vaginal gel
Experimental design
Eight adult female rabbits (New Zealand white species) 
weighing 1.5–1.7 kg were used for this study. The animals 
were divided into two groups both containing four animals 
each, and one animal was used as control. The animals 
were kept fasted for overnight. Water was given ad libitum 
during fasting and throughout experiment. The rabbits 
were not anesthetized during or prior to the experiment 
and were applied the formulation with the help of vaginal 
applicator and standard oral dose of pour drug with the 
help of oral cannula. The procedures employed in this 
study were approved by Institutional Ethical Committee 
(no: HPI/07/60/IAEC/0013). One group was fed with 
standard AZT at a dose of 2 mg. Two grams of vaginal 
gel (F3) was applied to other group with the help of 
vaginal applicator and marked as test “Formulationx”. 
Blood samples (2 mL) were collected from marginal ear 
vein at an interval of 1, 2, 4, 6, and 24 h during this study. 
The same method was followed for each group (both 
standard and test). The blood samples withdrawn as above 
were transferred to a series of graduated centrifuge tube 
containing 1 mL of 10% w/v EDTA solution.[17] The 
samples were centrifuged immediately at 3000rpm for 15 
min in cooling centrifuge machine to collect plasma.[18] 
The plasma was separated and transferred into other set 
of sample tubes and stored at –20°C until assayed. About 
1 mL plasma was mixed with 1 mL of 15 w/v% trichloro 
acidic acid (TCA), shaken well for 3 min and centrifuged 
at 3000rpm for 15 min. The plasma samples were analyzed 
for AZT by first passing the plasma samples through Silica 
gel column and analyzed by HPLC (LC-20 AT, Shimadzu, 
Japan) using mobile phase methanol:water (60:40)[19] at a 
flow rate of 1.2 mL/min. Twenty microliters of injection 
volume was eluted in RP C(18) column (4.6 mm × 150 mm) 
at room temperature. The column eluted was monitored at 
wavelength (λmax) 267 nm using diode array UV detector.
Pharmacokinetics analysis
The highest observed concentration during the study 
period; Cmax and time, at which Cmax observed, Tmax, were 
obtained directly from the plasma concentration time 
profiles. The area under the plasma concentration time 
curve (AUC0-24h, and AUC0-α, µg h/mL) was calculated 
based on the trapezoidal rule. The volume of distribution 
(Vd), total body clearance (ClT), elimination rate constant 
(KE), and half-life (t1/2) was also calculated.[20] 
Statistical analysis 
Analysis of Variance is presented as (mean+SD) and 
(P=0.05) was considered significant. Statistical data analyses 
were performed by statistical analysis using MYSTAT 
soft-ware the ANOVA one way at 5% level of significance   
P < 0.05.
RESULTS AND DISCUSSION
The generalized protocol depends on choice of ingredient, 
successful preparation of vaginal gels, and optimization 
at every preparative steps. The formulation code and 
composition of vaginal gel were presented in Table 1.
Percent yield, drug content, spreadability, extrudability, 
and bioadhesive strength of vaginal gels
The percent yields of Fs were calculated and found to be 
into the range of 98.97 ± 3.36 to 99.90 ± 0.05%w/w given 
in column 2 of Table 2. The drug content of Fs was found 
to be in the range of 96.24 ± 0.09 to 100.01 ± 0.19 mg/100 
g of gel as in column 3 of Table 2. Observations for 
spreadability study are in column 5 of Table 2. Spreadability 
of all vaginal gels of all Fs was in the range of 119.29 ± 
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0.02 to 158.12 ± 0.24 g cm/s. Extrudability study shown 
in column 4 of Table 2 was in the range of 84.0 ± 1.78 
to 97.0 ± 2.93 g/cm2. As the concentration of polymer 
increased the extrudability of Fs also decreased, because as 
the concentration of polymer increased weight required to 
extrude gel from tube also increases. Vaginal bioadhesive 
strengths of all Fs, using goat vagina, were found in the 
following order F4 > F3 > F2 > F1 accordingly. Thus, it 
was concluded that F4 showed the highest bioadhesive 
strength as in column 6 of Table 2.
In vitro drug release and drug release kinetics of gel 
formulations
Figure 1 and Table 3 compares the in vitro drug release 
profiles of all the four formulations. It can be seen that 
the drug release throughout the study period was more 
or less steady. Formulations F1 and F2, where Carbopol 
P940 and HPMC combination (1:1 and 1:2) were used, 
showed the t90 (time taken for 90% of drug released) 8 
and 10 h, respectively. The data obtained suggest that the 
concentration of the polymer used is inadequate to control 
the release of AZT. Separately, in the next stage, attempt 
was made to control the release using vaginal gel into the 
vagina. It is of profound interest that the release profile of 
formulations F3 and F4 with Carbopol P940 and HPMC 
combination (1:3 and 1:4) showed a drug release throughout 
the study period as desired. t90 was found to be 24 and 20 h 
for F3 and F4, and it was significantly different (P < 0.05) 
among the formulations. All the formulations were also 
analyzed for the drug release kinetics. Although drug release 
from all the bioadhesive vaginal gel formulations (F1–F4) 
was observed up to 24 h, the drug release mechanism of 
all Fs was found to be predominately influenced by the 
different bioadhesive polymers added. The mechanism of 
drug release from hydrophilic polymeric matrices involves 
solvent penetration, hydration and swelling of the polymer, 
diffusion of the dissolved drug in the matrix and erosion 
of the gel layer. On the basis of the Diffusion control 
studies Table 3 and Figure 1, it was observed that the F1 
(n = 0.447) and F3 (n = 0.514) underwent case I Fickian 
diffusion control, during the dissolution study. In case 
of Fickian release mechanism, the rate of drug release is 
much lesser with polymer relaxation (swelling/erosion). 
Therefore, the drug release was chiefly dependent on the 
diffusion through the matrix. Also, it was observed that the 
bioadhesive vaginal gels F2 (n = 0.564) and F4 (n=0.652) 
from column 10 of Table 3, underwent non-Fickian 
(anomalous) diffusion control during the drug release study, 
which indicated that polymer relaxation had a significant 
role in the drug release mechanism. In the non-Fickian 
(anomalous) case II release, the rate of drug release is due 
to the combined effect of drug diffusion and polymer 
relaxation. Nature of release of the drug from the vaginal 
gels was inferred based on the correlation coefficients 
obtained from the plots of the kinetic models.
On the basis of excellent bioadhesive strength   
(55.07 ± 0.02 g), high drug content (98.84 ±0.01% 
mg/100g of gel, soft in nature, extrudability (89 g ± 0.28 
g/cm2), spreadability (158.12 ± 0.24 g cm/s) and good 
release profile (released only 90.18 ± 0.03% up to 24 h in 
a constant manner) bioadhesive vaginal gel formulation F3 
was selected for further studies.
In vivo studies of F3
F3 formulation containing the ratio (1:3) and pure drug 
Table 2: % Yield, drug content, extrudability, spreadability, and bioadhesive strength of bioadhesive vaginal gel
Formulation code % Yield* Drug Content (mg/100 g of gel)* Extrudability (g/cm2)* Spreadability (g.cm/sec)* Bioadhesive strength (g)*
F1 99.85 ± 1.05 96.24 ± 0.09 94 ± 1.02 135.43 ± 0.31 43.41 ± 0.05
F2 99.37 ± 1.26 98.81 ± 0.65 97 ± 2.93 127.36 ± 0.24 45.33 ± 0.03
F3 99.90 ± 0.05 98.84 ± 0.01 89 ± 0.28 158.12 ± 0.24 55.07 ± 0.02
F4 98.97 ± 3.36 100.01 ± 0.19 84 ± 1.78 119.29 ± 0.02 60.12 ± 0.01
*All values are expressed in mean ± standard deviation (n = 3)
Table 3: Drug release and drug release kinetics of bioadhesive Vaginal Gel
Formulations Cumulative % Drug 
release, %CR*
Zero-order release,  
K0
First-order  
release
Higuchi square root 
equation
Korsmeyer and Peppas 
equation
K0 r2 K1 r2 Kh r2 r2 n
F1 99.42 ± 0.52 (12 h) 7.74 0.89 0.18 0.91 30.25 0.98 0.98 0.447
F2 98.67 ± 0.05 (12 h) 7.32 0.96 0.12 0.67 27.25 0.96 0.99 0.564
F3 90.18 ± 0.03 (24 h) 3.05 0.66 0.04 0.97 17.64 0.94 0.99 0.514
F4 96.45 ± 0.02 (24 h) 4.09 0.82 0.08 0.79 22.16 0.97 0.99 0.652
aAll values are expressed in mean ± standard deviation (n = 3)
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Table 4: Pharmacokinetic parameter comparison with 
oral standard of bioadhesive vaginal gel
Parameter Standard dose  
(oral)
Bioadhesive vaginal gel 
(F3)
Cmax 18.494 μg mL–1 17.659 μg mL–1
Tmax 2 h 4 h
AUC
0
4 ∞
∫ () µgh/mL 182.02 μg h2 mL–1 225.507 μg h2 mL–1
AUMC
0
2 ∞
∫ () µgh/ mL 848.23 μg h2 mL–1 1831.377 μg h2 mL–1
MRT 4.66 h 8.21 h
T1/2 1 h 1 h
KE 0.693 h 0.693 h
Vd 0.680 lt/kg 0.070 lt/kg
Cl 0.047 lt/kg/h 0.48 lt/kg/h
Bioavailability (F) 100 (consider) 123.89%
Dose administered 2 mg 2 mg
Figure 1: Drug diffusion profiles of bioadhesive vaginal gel (F1–F4) Figure 2: Plasma drug concentration profiles of bioadhesive vaginal 
gel with oral standard 
solution (1 mg/mL) after oral administration were used 
to plot percent plasma concentrations versus time curve 
[Figure 2] for Zidovudine. Pharmacokinetic parameters 
for both are presented in Table 4. F3 formulation of AZT 
showed (Cmax) 17.659 μg mL-1 in blood as compared to 
pure drug solution 18.494 μg mL-1 and bioavailability (F) 
123.89% as compared with pure drug solution (considered 
100%). Tmax of F3 was 4 h, and pure drug solution 
was 2 h. AUC is an important parameter for evaluating 
bioavailability of drug from dosage form as it represents 
the total integrated area under the blood concentration time 
profile and represents the total amount of drug reaching. 
The F3 formulation and pure drug solution wear not a 
statistically significantly different (P < 0.05) indicated that 
drug amount between the formulations did not vary.
CONCLUSION
F3 formulation containing carbopol–HPMC (1:3) was 
selected and evaluated for this study. In vitro drug release 
study of F3 showed t90 in 24h drug released following case 
I Fickian (n≤0.5) transport mechanism. In case of in vivo 
drug release it was found  that (Tmax) 4h and (Cmax) 17.659 
μg ml-1, bioavailability (F) 123.89 % comparison with oral 
standard drug solution. It also shows good extrudability, 
spreadability, and good bioadhesive strength. Further 
research in this area will surely expected to yield significant 
outcome with improved vaginal drug delivery system for 
the treatment of AIDS and its prevention.
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